期刊文献+

HPLC-ESI-MS联用法测定大鼠血浆中KJY-01浓度及其药动学研究 被引量:1

HPLC-ESI-MS determination of KJY-01 in rat plasma and pharmacokinetics research
下载PDF
导出
摘要 目的建立测定KJY-01大鼠血浆中药物浓度的高效液相色谱。电喷雾离子化。质谱(HPLC—ESI-MS)联用的分析方法,对其进行大鼠体内的药动学研究。方法取大鼠血浆50μL,加入内标酮康唑,用甲醇提取后取上清液吹干,用80%甲醇100μL溶解,取2μL进行HPLC-MS测定。色谱柱为Agilent ZORBAX Eclipse plus C18(150mm×2.1mm,5μm),流动相为20mmol醋酸铵(甲酸调节PH为3.75):甲醇(含1‰的甲酸)=22:78,流速为0.25mL/min,采用选择离子检测(SIM)法检测SQ109(m/z=331.3),KJY-01(m/z=475.4),酮康唑(内标,m/z=531.2)。结果SQ109的血药浓度在10~5000ng/mL范围内线性关系良好,最低检测限为10ng/mL,以质控样品计算,在各浓度水平下,此法的回收率均大于80%,日间和日内精密度小于20%,符合生物样品分析要求。结论该方法操作简便、快速、灵敏、专属性强,可用于KJY-01的大鼠体内大批量样品定量分析及早期药动学研究。 Objective To develop an HPLC-ESI-MS method for the determination of KJY-01 in rat plasma and the pharmacokinetic study of KJY-01. Methods The internal standard (Ketoconazole) was added to 50μL rat plasma,then extracted with methanol and evaporated,the residue was dissolved with 80% methanol and determined by injecting 2μLto HPLC-MS system.The Agilent ZORBAX Eclipse plus C18(150mm×2. 1mm, 5μm)column was adopted. The mobile phase was consisted of 20mmol ammonium acetate(pH 3.75 adjusted by formic acid)-methanol including 1‰ formic acid(22: 78). Selected Ion Mass(SIM) was used to determine SQ 109(m/z=331.3), KJY-01 (m/z=475.4), Ketoconazole(IS, m/z=531.2). Results The assay had a calibration range from 10 to 5000 ng/mLand the lowest limit of quantification (LOQ) of 10 ng/mL for SQ109. The recovery was above 80%. The intra-and inter-day RSDs were less than 20%. Conclusion This method is proved to be convenient, rapid, sensitive and suitable for pharmacokinetic study of KJY-01.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2011年第6期474-477,共4页 Chinese Journal of Antibiotics
基金 中华人民共和国政府"十一五"计划"重大新药创制专项"资金资助 专项号:2009ZX09103-054
关键词 KJY-01 SQ109 高效液相色谱-电喷雾离子化-质谱联用法 药动学 血药浓度 KJY-01 SQ109 HPLC-ESI-MS Pharmacokinetics Drug plasma concentration
  • 相关文献

参考文献6

  • 1Umesh G. Lalloo,Anish Ambaram.New Antituberculous Drugs in Development[J].Current HIV / AIDS Reports.2010(3)
  • 2Burman W J.Rip Van Winkle wakes up:development of tuberculosis treatment in the 21st century[].Clinical Infectious Diseases.2010
  • 3Jia L,Noker P E,Coward L,et al.Interspecies pharmacokinetics and in vitro metabolism of SQ109[].British Journal of Pharmacology.2006
  • 4Amit N,Rahul J.Recent advances in new structural classes of anti-tuberculosis agents[].Current Medicinal Chemistry.2005
  • 5Rivers EC,Mancera RL.New anti-tuberculosis drugs with novel mechanisms of action[].Current Medicinal Chemistry.2008
  • 6Jia L,Tomaszewski JE,Hanrahan C, et al.Pharmacodynamics and pharma-cokinetics of SQ109,a new diamine-based antitubercular drug[].British Journal of Pharmacology.2005

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部